RALA and chronic myelogenous leukemia, BCR-ABL1 positive: To provide evidence supporting the in vivo pharmacological inhibitory effect of RalA on CML, a CML mouse model was adopted for testing the effects of exposure to the RalA inhibitor RBC8.